
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is well-positioned in the oncology market with promising drug candidates and a strong revenue stream through out-licensing agreements. However, there are risks in terms of competition and the success of their drugs in clinical trials. The acquisition of safusidenib and focus on business development show potential for future growth and expansion in the oncology market.
Bears say
Nuvation Bio is facing potential challenges in the future due to competition from other companies, which may limit its ability to maintain profitability and market leadership. Additionally, the company has not yet achieved FDA approval for its product candidate, which could lead to delays in generating revenue. Finally, while Nuvation Bio's clinical stage pipeline is promising, its current annualized sales run-rate is relatively low compared to its potential peak sales, which may cause concerns among investors about its revenue growth potential.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares